The Federal Government has announced a $69 million boost to support Australian researchers in their fight against rare cancers and rare diseases.
More than $26 million has been made available for 19 research projects as part of the landmark Medical Research Future Fund’s Rare Cancers, Rare Diseases and Unmet Needs Clinical Trials Program.
University of Queensland (UQ) researchers have been awarded a share in the funding for a clinical trial that aims to evaluate the benefits of medicinal cannabis for people with advanced cancer, and define the role of the drug for patients with cancer in palliative care.
Professor Janet Hardy, the research team leader from UQ said information from this study is urgently required to inform future prescribing practices, research and health policy.
“We will conduct the first clinical trial worldwide to rigorously evaluate the efficacy, safety and acceptability of medicinal cannabinoids for symptom relief in advanced cancer patients receiving palliative care. The study will be a randomised, blinded, placebo controlled trial that will define the role of medicinal cannabis in the care of these patients.”
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >